A Novel EPAC-Specific Inhibitor Suppresses Pancreatic Cancer Cell Migration and Invasion

Muayad Almahariq, Tamara Tsalkova, Fang C. Mei, Haijun Chen, Jia Zhou, Sarita K. Sastry, Frank Schwede, and Xiaodong Cheng

Department of Pharmacology and Toxicology (M.A., T.T., F.C.M., H.C., J.Z., X.C.) and Sealy Center for Structural Biology and Molecular Biophysics (X.C.), Department of Biochemistry and Molecular Biology (S.K.S.), The University of Texas Medical Branch, Galveston, Texas; and BIOLOG Life Science Institute, Forschungslabor und Biochemica-Vertrieb GmbH, Bremen, Germany (F.S.)

Received June 17, 2012; accepted October 11, 2012

ABSTRACT
Exchange protein directly activated by cAMP (EPAC) and cAMP-dependent protein kinase (PKA) are two intracellular receptors that mediate the effects of the prototypic second messenger cAMP. Identifying pharmacological probes for selectively modulating EPAC activity represents a significant unmet need within the research field. Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel non-cyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. Using this novel EPAC-specific inhibitor, we have probed the functional roles of overexpression of EPAC1 in pancreatic cancer cells. Our studies show that EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.

Introduction
The major physiologic effects of cAMP in mammalian cells are transduced by two ubiquitously expressed intracellular cAMP receptor families: the classic protein kinase A/cAMP-dependent protein kinase (PKA/cAPK) and the more recently discovered exchange protein directly activated by cAMP/cAMP-regulated guanine nucleotide exchange factor (EPAC/cAMP-GEF) (Cheng et al., 2008). Similar to PKA, EPAC contains an evolutionarily conserved cAMP-binding domain (CBD) that acts as a molecular switch for sensing intracellular levels of the second messenger cAMP, and activates the downstream signaling molecules small GTPases Rap1 and Rap2 (de Rooij et al., 1998; Kawasaki et al., 1998). In addition, EPAC proteins exert their functions through interactions with other cellular partners at specific cellular loci. For example, EPAC1 is known to associate with mitotic spindle, plasma membrane, and nuclear membrane by interacting with tubulin (Qiao et al., 2002; Mei and Cheng, 2005), ezrin-radixin-moesin (ERM) proteins (Gloerich et al., 2010; Ross et al., 2011), and nucleoporin RanBP2 (Liu et al., 2010; Gloerich et al., 2011), respectively. On the other hand, EPAC2 can interact with Rim (Rab3 interacting molecule) and Rim2 (Ozaki et al., 2000; Kashima et al., 2001), as well as a structurally related calcium sensor Piccolo (Fujimoto et al., 2002). In pancreatic β cells, interactions among EPAC2, Rim2, and Piccolo are critical for cAMP-mediated insulin secretion (Ozaki et al., 2000; Kashima et al., 2001; Fujimoto et al., 2002).

More than a decade of extensive studies have now firmly established that many cAMP-related cellular processes previously thought to be controlled by PKA alone are also mediated by EPAC (Gloerich and Bos, 2010). For example, EPAC proteins have been implicated in regulating exocytosis and secretion (Ozaki et al., 2000; Maillet et al., 2003; Seino and Kashima et al., 2001), as well as a structurally related calcium sensor Piccolo (Fujimoto et al., 2002). In pancreatic β cells, interactions among EPAC2, Rim2, and Piccolo are critical for cAMP-mediated insulin secretion (Ozaki et al., 2000; Kashima et al., 2001; Fujimoto et al., 2002).

This work was supported by the National Institutes of Health National Institute of General Medicine [Grant R01GM086170], a training fellowship from the Keck Center for Interdisciplinary Bioscience Training of the Gulf Coast Consortium funded by the National Institutes of Health National Institute of General Medicine [Grant T32GM089657] and, in part, by the John S. Dunn Foundation through the Gulf Coast Consortium for Chemical Genomics. M.A., T.T., and F.C.M. contributed equally to the study.

This article has supplemental material available at molpharm.aspetjournals.org.

ABBREVIATIONS: 807. 8-(4-Chlorophenylthio)-2’-O-methyladenosine-3’5’-cyclic monophosphate; 007-AM, 007 acetoxymethyl ester; CBD, cAMP-binding domain; DMSO, dimethyl sulfoxide; EPAC, exchange protein directly activated by cAMP; FBS, fetal bovine serum; Gef, guanine nucleotide exchange factor; HTS, high-throughput screening; Mant-GDP, 2’3’-O-(N’-methylanthraniloyl)guanosine-5’-O-diphosphate; 8-NBD-cAMP, 8-[2’-N-nitro-4-benzofurazanyl]aminoethylthio)adenosine-3’5’-cyclic monophosphate; PBS, phosphate-buffered saline; PDA, pancreatic ductal adenocarcinoma; PKA, protein kinase A/cAMP-dependent protein kinase; Rap, Ras-proximate.
et al., 2005) and hedgehog signaling (Ji et al., 2007). On the other hand, depending upon the specific cellular context, EPAC and PKA can exert synergistic effects on downstream signaling such as stimulation of neurotensin secretion (Li et al., 2007) and attenuation of cAMP signaling through phosphodiesterases (Dodge-Kafka et al., 2005). Despite these significant advances in our knowledge, the lack of EPAC-specific antagonists has greatly limited our ability to discern the physiologic functions of this family of proteins and understand their role in numerous diseases. For example, EPAC1 is overexpressed in human pancreatic ductal adenocarcinoma (PDA) specimens (Lorenz et al., 2008), but the implications of this overexpression are unclear. To address the lack of EPAC inhibitors, we have developed a robust high-throughput screening (HTS) assay for identifying new chemical probes specifically targeting EPAC proteins (Tsalkova et al., 2012a). In this study, we describe the identification and characterization of 3-[(5-tert-butyl-isoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazonol-3-oxo-propionitrile (ESI-09), a novel EPAC-specific inhibitor, which enabled us to demonstrate that EPAC1 plays an important role in pancreatic cancer cell migration and invasion.

Materials and Methods

Reagents. 8-(4-Chlorophenylthio)-2’-O-methyladenosine-3’,5’-cylic monophosphate, acetoxyethyl ester (007-AM), initially provided by and subsequently purchased from BioLog Life Science Institute (Bremen, Germany), is the highly membrane-permeant and potent acetoxyethyl ester prodrug (Vliem et al., 2008; Chepurny et al., 2009) of 8-(4-chlorophenylthio)-2’-O-methyladenosine-3’,5’-cyclic monophosphate (007), the first selective EPAC agonist that is more than 100-fold less potent for PKA (Enserink et al., 2002; Christensen et al., 2003). After cell penetration of the uncharged prodrug, the active parental compound 007 is released by endogenous esterases and trapped inside the cell due to the negatively charged cyclic phosphate moiety. 8-[(2-[7-Nitro-4-benzofurazanyl]amino)ethyl(thio)adenosine-3’,5’-cyclic monophosphate (8-NBD-cAMP) was also obtained from BioLog Life Science Institute. 2’-3’-O-(N’-methylene)anthraniloylguanosine-5’-O-diphosphate (Mant-GDP) was purchased from Molecular Probes, Invitrogen (Carlsbad, CA). All other reagents and compounds (Maybridge; Thermo Fisher Scientific, Trevillett, UK) was obtained from BioLog Life Science Institute. 2’-3’-O-(N’-methylene)anthraniloylguanosine-5’-O-diphosphate (Mant-GDP) was purchased from Molecular Probes, Invitrogen (Carlsbad, CA). All other reagents and compounds (Maybridge; Thermo Fisher Scientific, Trevillett, UK) was obtained from BioLog Life Science Institute. 2’-3’-O-(N’-methylene)anthraniloylguanosine-5’-O-diphosphate (Mant-GDP) was purchased from Molecular Probes, Invitrogen (Carlsbad, CA). All other reagents and compounds (Maybridge; Thermo Fisher Scientific, Trevillett, UK) was obtained from BioLog Life Science Institute.

Antibodies. Antibodies specific against Akt (#9272), phosho-Akt (T308) (#4066), phosho-Akt (S473) (#9271), EPAC1 (#4155), and EPAC2 (#4156) were purchased from Cell Signaling Technology (Danvers, MA), while anti-Rap1 antibody (SC-65) was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Protein Expression and Purification. Recombinant EPAC1, EPAC2, and C-terminal truncated Rap1B(1-167) were purified as described previously (Mei and Cheng, 2005; Li et al., 2011). PKA RIA, RIB, and catalytic subunits were recombinantly expressed in Escherichia coli and purified to homogeneity as reported (Cheng et al., 2001). Type I and II PKA holoenzymes were reconstituted from individually purified recombinant PKA R and C subunits (Yu et al., 2004). All proteins used in this study were at least 95% pure, as judged by SDS-PAGE.

HTS. Fluorescence intensity of 8-NBD-cAMP in complex with EPAC2 has been used as a primary signal in HTS (Tsalkova et al., 2012a). A primary screen of the Maybridge HitFinder collection of compounds (Maybridge; Thermo Fisher Scientific, Trevillett, UK) was performed in black 384-well low-volume microplates (Corning Costar, Cambridge, MA). In brief, a protein solution containing 65 nM EPAC2 and 75 nM 8-NBD-cAMP was dispensed into 384-well plates (35 μl/ well) using the Biomek FX Laboratory Automation Workstation equipped with a 96-multichannel pipetting head (Beckman Coulter, Brea, CA). Test compounds (1 μl/well) were added from 10 mM stock solutions in DMSO. DMSO or cAMP at 10 mM was used as a negative or positive control, respectively. Fluorescence intensity signal was recorded at room temperature before and after tested compounds were added using the SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA) with excitation/emission wavelengths set at 470/540 nm.

In Vitro GEF Activity Assay of EPAC Proteins. In vitro EPAC activity was measured using purified Rap1B(1-167) loaded with Mant-GDP as previously described (Tsalkova et al., 2009).

In Vitro PKA Activity Assay. PKA kinase activities of the type I and II PKA holoenzymes were measured spectrophotometrically with a coupled enzyme assay using purified and reconstituted recombinant PKA holoenzymes (Cook et al., 1982).

Cell Culture. AsPC-1 and PANC-1 cells with suppressed EPAC1 expression were generated using MISSION TRC (Sigma-Aldrich, St. Louis, MO) lentiviral-based short hairpin RNA according to the manufacturer’s protocol. AsPC-1 and PANC-1 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a humidified atmosphere of 5% CO2 at 37°C.

Fig. 1. Chemical structure of ESI-09.

Fig. 2. Relative potency of ESI-09. (A) dose-dependent competition of ESI-09 (open circles) and cAMP (closed squares) with 8-NBD-cAMP in binding to EPAC2. (B) dose-dependent inhibition of EPAC1 (closed circles) or EPAC2 (open circles) GEF activity by ESI-09 in the presence of 25 μM cAMP.
in RPMI 1640 medium with 10% fetal bovine serum (FBS). INS-1 cells (passage numbers 70–90) were maintained in RPMI 1640 medium containing 10 mM Hepes, 10% FBS, 2.0 mM l-glutamine, 1.0 mM sodium pyruvate, and 50 µM 2-mercaptoethanol. All cells were kept in a humidified incubator (95% air, 5% CO2) at 37°C.

**Phosphorylation of Akt.** Cells were starved of serum for 24 hours before treatment with ESI-09 for 5 minutes. Cells were then treated with 10 µM 007-AM for 15 minutes, and cellular proteins were extracted in SDS lysis buffer (2% SDS, 10% glycerol, 60 mM Tris, pH 6.8). Nontreated cells and cells treated with 10 µM 007-AM only were used as negative and positive controls, respectively. Approximately 10 µg of total protein extract was separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. Akt phosphorylation was probed with anti-phospho-Akt T308 and S473 antibodies (1:1000). Phosphorylation levels were determined with densitometry and expressed as a percentage of basal Akt phosphorylation (negative control). At least three independent experiments were performed for each Western blot.

**Insulin Secretion Assay.** INS-1 cells were plated in 96-well plates precoated with polylysine at a density of 1 × 10⁶ cells/well. After overnight incubation, the medium was replaced with Krebs-Ringer bicarbonate (KRB) containing 2.9 mM glucose. After an additional 2-hour incubation, the cells were treated with ESI-09 or DMSO vehicle as a control in fresh KRB containing 11.8 mM glucose for 10 minutes, followed by a 30-minute stimulation with 10 µM 007-AM. The supernatant was collected, and insulin was quantified using an Ultra Sensitive Rat Insulin ELISA kit from Crystal Chem Inc. (Downers Grove, IL).

**Transwell Migration/Invasion Assay.** The top chambers of 8-micron inserts (Costar Inc.) were coated with BD Matrigel Basement Membrane Matrix (50 µg/ml) (BD Biosciences, San Jose, CA). Cells (2 × 10⁵) pretreated with ESI-09 for 24 hours were added to the top chamber of the inserts in serum-free RPMI 1640 medium containing 0.25% bovine serum albumin. The bottom chamber was filled with 600.0 µl of RPMI containing 10% FBS and ESI-09. The cells were then incubated at 37°C in 5% CO₂ for 20 hours. Cells were removed from the top chamber, and migrated cells were fixed in methanol and stained with crystal violet. The numbers of migrated cells were counted in four different fields. Three independent experiments were performed for each ESI-09 concentration.

**Wound Healing Assay.** Cells were grown to 95%–100% confluence before a scratch wound was made. The medium was changed to RPMI 10% FBS containing 10 µM ESI-09 or vehicle. The cells were then incubated at 37°C in 5% CO₂. The wound was imaged at 0 and 22 hours after changing the medium. Healing rate was determined.
by calculating the percentage of wound closure according to the following equation: % wound closure = (initial wound width – wound width 22 hours post-treatment with ESI-09 or vehicle)/initial wound width × 100.

To make the results comparable across all assays, the widths of the initial wounds were all normalized to a 1-mm distance.

**Cell Adhesion Assay.** Cells were serum-starved for 24 hours in RPMI 1640, detached using 0.25% trypsin-EDTA, and washed twice with serum-free RPMI 1640 before treatment with ESI-09 for 15 minutes. The cells were then treated with 10 μM 007-AM and ∼3 × 10⁶ cells in 100 μl RPMI 1640 were immediately added to each well of a non-tissue-culture-treated EIA/RIA 96-well plate (Corning Life Sciences (Lowell, MA). Nontreated cells and cells treated with 10 μM 007-AM only were used for comparison. The plates were previously coated with collagen I for 2 hours (10 g/ml in phosphate-buffered saline [PBS]) and blocked with 5% bovine serum albumin in PBS for 1 hour at 37°C. The plates were incubated at 37°C for 1 hour, and unattached cells were removed by washing twice with PBS. The cells were fixed with 3.7% formaldehyde in PBS for 10 minutes and stained with trypan blue. The attached cells were counted, and the percentage of adherent cells in each treatment group was calculated using the following equation: % adhesion = number of adherent cells in treatment group/number of adherent cells in nontreatment group × 100.

The adhesion assays were repeated three times.

**Results**

**Identification and Biochemical Characterization of ESI-09.** We developed a sensitive and robust HTS assay (Tsalkova et al., 2012a) based on the principle that fluorescence intensity of a cAMP analog, 8-NBD-cAMP, is environmentally sensitive. Binding of 8-NBD-cAMP to purified full-length EPAC2 led to a >100-fold increase in fluorescence signal. This increase was competitively reversed by the binding of cAMP (Supplemental Fig. 1). Through HTS of the Maybridge Hit-Finder diversity library with 14,400 drug-like chemicals, we identified 3-[5-(tert-butyl)isoxazol-3-yl]-2-[2-(3-chlorophenyl)hydrazono]-3-oxopropanenitrile, referred to as ESI-09 (Fig. 1), which was capable of reducing both EPAC1 and EPAC2 GEF activity to basal levels at 25 μM concentration in the presence of an equal concentration of cAMP (Tsalkova et al., 2012b). After the initial identification of the hit, individually vialed and highly purified ESI-09 was purchased from Maybridge and its chemical structure and purity were validated by ²H and ¹³C NMR as well as mass spectrometry analysis. We then performed dose-dependent titrations to determine the relative binding affinity of ESI-09. When various amounts of cAMP or ESI-09 were added to the reaction mixture, with fixed concentrations of EPAC2 and 8-NBD-cAMP, a concentration-dependent decrease in 8-NBD-cAMP fluorescence was observed (Fig. 2A). While cAMP competed with 8-NBD-cAMP binding with an apparent IC₅₀ of 39 ± 2.0 μM, ESI-09 showed an increased potency with an apparent IC₅₀ of 10 ± 1.2 μM. To determine whether this apparent higher-affinity binding of EPAC2 antagonists can be translated to a high potency in suppressing the GEF activity of EPAC2, we determined the inhibition curves of EPAC-catalyzed Rap1-GDP exchange activity for ESI-09 in the presence of 25 μM cAMP. As shown in Fig. 2B, ESI-09 inhibited cAMP-mediated EPAC2 GEF activity with an apparent IC₅₀ of 1.4 ± 0.1 μM. Similarly, ESI-09 was also effective in suppressing cAMP-mediated EPAC1 GEF activity with an apparent IC₅₀ of 3.2 ± 0.4 μM.

To determine the specificity of ESI-09, we performed counterscreening assays that measured type I and II PKA holoenzyme activities. An ESI-09 concentration of 25 μM did not significantly alter cAMP-induced type I or II β PKA holoenzyme activation, whereas H89, a selective PKA inhibitor, blocked type I and II PKA activities completely (Supplemental Fig. 2). When tested at 100 μM concentration, ESI-09 inhibited type II PKA activity up to 20% in the presence of 100 μM cAMP. These data suggest that ESI-09 is at least 100 times more selective for EPAC proteins than PKA.

**Molecular Docking of ESI-09 into the CBDs of EPAC1 and EPAC2.** To gain insights into the structural basis for the binding of ESI-09 to the EPAC proteins, the intermolecular

---

**Fig. 4.** ESI-09 inhibits EPAC- but not EGF-mediated Akt phosphorylation in AsPC-1 pancreatic cancer cells. Serum-starved AsPC-1 cells were stimulated with vehicle, 10 μM 007-AM, or 0.1 μM EGF after pretreatment with the indicated concentrations of ESI-09. Cell lysates were subjected to Western blot analyses using anti-phospho-Akt T308 and S473 antibodies (representative blot shown). Data points represent mean ± S.D. (n = 3). #Significantly higher than vehicle group (P < 0.02). *Significantly lower that 007-AM-stimulated group (P < 0.02).

**Fig. 5.** ESI-09 inhibits EPAC2-mediated insulin secretion in INS-1 cells. INS-1 cells were stimulated with vehicle or 10 μM 007-AM after pretreatment with the indicated concentrations of ESI-09. Bars represent mean ± S.D. (n = 3). #Significantly higher than vehicle group (P < 0.05). *Significantly lower that 007-AM-stimulated group (P < 0.05).
interactions of ESI-09 with EPAC1 and EPAC2 were analyzed and compared by molecular docking (Trott and Olson, 2010) using the cAMP-bound EPAC2 crystal structure (3CF6) (Rehmann et al., 2008) and a three-dimensional homology model of EPAC1 (Arnold et al., 2006). AutoDock Vina docking results revealed that ESI-09 could be docked to the CBD of EPAC1 and EPAC2, with better energetic scores than those for cAMP. ESI-09 could fit well into the functional cAMP-binding pocket of EPAC1, establishing favorable hydrophobic and hydrogen bonding interactions with the protein’s active-site residues. The tert-butyl-isoxazolyl moiety of ESI-09 could extend to a deep hydrophobic pocket around Phe268 and Met312, with its 3-chloro-phenyl fragment close to the hydrophobic pocket around Ala281 and Leu314. Moreover, ESI-09 could form five putative hydrogen bonds with the residues Gly269, Gln270, Leu271, Ala280, and Ala281 (Fig. 3, A and B). With EPAC2, the tert-butyl-isoxazolyl moiety could interact with a hydrophobic pocket formed by Phe367, Leu406, Ala407, and Ala415, while residues Val386, Val394, Leu397, Ala416, and Leu448 could form hydrophobic interactions with the 3-chloro-phenyl fragment of ESI-09. Meanwhile, the tert-butyl-isoxazolyl moiety could form a hydrogen bond with the residue Gly404 of EPAC2 (Fig. 3, C and D). These docking observations are in full agreement with the experimental EPAC inhibition results as shown in Fig. 2, and provide useful information to assist our ongoing efforts to design and synthesize more potent and specific inhibitors based on ESI-09 as a chemical lead.

Cellular Characterization of ESI-09. To test whether our newly identified EPAC antagonist ESI-09 is capable of modulating EPAC activation in living cells, we monitored its ability to suppress Akt phosphorylation, as EPAC proteins are also known to activate Akt signaling, whereas PKA inhibits it (Mei et al., 2002). To determine whether ESI-09 is capable of blocking EPAC-mediated Akt activation, the phosphorylation status of T308 and S473 of Akt in the pancreatic cancer cell line AsPC-1, which overexpresses EPAC1, was followed using anti-phospho-Akt antibodies. As shown in Fig. 4, ESI-09 inhibited 007-AM-stimulated Akt phosphorylation at T308 and S473 in a dose-dependent manner. Similar results were observed in the rat pancreatic β-cell line INS-1 (Supplemental Fig. 3). On the other hand, ESI-09 failed to suppress epidermal growth factor (EGF)-induced phosphorylation of Akt in AsPC1 cells (Fig. 4).

After demonstrating that ESI-09 was capable of inhibiting EPAC-mediated Akt phosphorylation in cell culture, we
proceeded to determine whether ESI-09 was capable of suppressing EPAC-mediated physiologic functions. EPAC proteins, particularly EPAC2, have been implicated in regulating cAMP-mediated exocytosis in a variety of secretory cells (Seino and Shibasaki, 2005). In pancreatic endocrine β cells, EPAC mediates the glucose-induced insulin secretion potentiated by glucagon-like peptide 1 and gastric inhibitory polypeptide, which bind to receptors on the surface of β cells and promote intracellular cAMP production (Leech et al., 2000; Kashima et al., 2001; Kang et al., 2003; Shibasaki et al., 2007). When INS-1 was stimulated by 007-AM, a steady increase in insulin secretion was observed. This EPAC-mediated increase in the level of insulin secretion was inhibited in a dose-dependent manner by preincubation of the cells with ESI-09 (Fig. 5). The impact of ESI-09 on EPAC-mediated Akt phosphorylation and insulin secretion is consistent with the biochemical Rap1 nucleotide exchange data shown in Fig. 2B and demonstrates that this small molecule is a pan-EPAC inhibitor that is capable of suppressing EPAC cellular functions.

**ESI-09 inhibits Pancreatic Cancer Migration.** Increased levels of EPAC1 expression have been observed in human PDA compared with normal pancreas or surrounding tissue (Lorenz et al., 2008). However, the functional role of EPAC1 elevation in this neoplasm remains unclear. We sought to employ ESI-09 to determine the role of EPAC1 signaling in pancreatic cancer. Treatment of pancreatic cancer cells with ESI-09 did not significantly affect cell proliferation and viability (Supplemental Fig. 4). On the other hand, when the pancreatic cancer cell lines AsPC-1 and PANC-1 were pretreated with ESI-09, a significant decrease in cell migration was observed using both Transwell migration/invasion and wound healing assays (Fig. 6, A and B). To determine whether the observed impact on cell migration is EPAC1-specific, we examined the effect of suppressing EPAC1 expression on AsPC-1 and PANC-1 migration using RNA interference. Short hairpin construct shEPAC1 clone C28 led to a near complete knockdown of EPAC1 expression and significantly inhibited migration of both cell lines, whereas a partial reduction of EPAC1 expression by shEPAC1 clone C32 decreased AsPC-1 and PANC-1 cell migration slightly, but the changes were not significant (Fig. 6C). These results, combined with the fact that pancreatic cancer cells do not express detectable levels of EPAC2 (Supplemental Fig. 5), suggest that EPAC1 might play an important role in pancreatic cancer cell migration and invasion. To further determine how ESI-09 inhibits PDA cell migration and invasion, we performed a cell adhesion assay on a collagen I matrix. As shown in Fig. 7, 007-AM led to an increase in cell adhesion for both AsPC-1 and PANC-1 cells, whereas pretreatment with ESI-09 decreased 007-AM-induced cell adhesion dose-dependently.

**Discussion**

Taken together, our results show that we have successfully identified ESI-09, a noncyclic nucleotide small molecule that specifically inhibits EPAC1 and EPAC2. Consistent with its EPAC inhibition activity observed in a biochemical assay, ESI-09 also inhibited several well known EPAC-mediated cellular functions, including Akt phosphorylation and insulin secretion. To the best of our knowledge, this is the first report of discovery and characterization of a small-molecule inhibitor of the EPAC family of proteins since their initial discovery in 1998. McPhee et al. (2005) reported the discovery of compounds capable of competing with 3H-cAMP for binding with the isolated CBDs of EPAC1 and EPAC2. However, it has not been shown that these compounds are capable of inhibiting EPAC functions biochemically or in cells. The discovery of an EPAC-specific antagonist may have immense implications for cAMP biology, as it will provide a means to pharmacologically dissect the roles of EPAC proteins in various cellular and diseases processes.

PDA is one of the most lethal human diseases, largely due to the fact that pancreatic cancer is resistant to treatments that are usually effective for other types of cancer. A better understanding of the molecular mechanism of PDA development and metastasis and novel, effective therapeutics are desperately needed. Recently, it has been shown that EPAC1 is markedly elevated in human PDA cells compared with normal pancreas or surrounding tissue (Lorenz et al., 2008). Although EPAC1 has been implicated in promoting cellular proliferation in prostate cancer (Misra and Pizzo, 2009, 2012) and migration and metastasis in melanoma (Baljinnyam et al., 2009, 2010, 2011), the role of EPAC1 in pancreatic cancer has never been investigated. Using our novel EPAC inhibitor ESI-09, we have demonstrated a functional role of EPAC1 overexpression in pancreatic cancer cell migration and invasion. These findings are consistent with similar results based on RNA interference silencing techniques, suggesting that EPAC1 may represent a potential target for developing novel therapeutic strategies for PDA.

**Acknowledgments**

The authors are grateful to Dr. George Holz for providing the INS-1 cells and advice on insulin secretion analysis. The authors also thank Dr. Alfred Wittinghofer (Abteilung Strukturelle Biologie Max-Planck-Institut für molekulare Physiologie) and Dr. Holger Rehmann.